Figure 4.
Multivariable risk classification of patients with RRMM according to ctDNA mutations. (A) Kaplan-Meier survival curves of 161 RRMM cases (having both BMPC-seq and ctDNA-seq data) stratified by the RRMM-PI score. This scoring system assigns 3 points to ≥2 ctDNA mutations; 2 points to 1 ctDNA mutation, ≥3 prior regimens, and t(11;14) rearrangement; and 1 point to high plasma DNA concentration. (B) Kaplan-Meier survival curves of 161 RRMM cases stratified by the ctRRMM-PI score. This scoring system assigns 2 points to ≥2 ctDNA mutations and ≥3 prior regimens; and 1 point to 1 ctDNA mutation and high plasma DNA concentration. (C) Kaplan-Meier survival curves of 98 validation cases (having BMPC-seq data but not ctDNA-seq data) stratified by the ctRRMM-PI score. Log-rank test.

Multivariable risk classification of patients with RRMM according to ctDNA mutations. (A) Kaplan-Meier survival curves of 161 RRMM cases (having both BMPC-seq and ctDNA-seq data) stratified by the RRMM-PI score. This scoring system assigns 3 points to ≥2 ctDNA mutations; 2 points to 1 ctDNA mutation, ≥3 prior regimens, and t(11;14) rearrangement; and 1 point to high plasma DNA concentration. (B) Kaplan-Meier survival curves of 161 RRMM cases stratified by the ctRRMM-PI score. This scoring system assigns 2 points to ≥2 ctDNA mutations and ≥3 prior regimens; and 1 point to 1 ctDNA mutation and high plasma DNA concentration. (C) Kaplan-Meier survival curves of 98 validation cases (having BMPC-seq data but not ctDNA-seq data) stratified by the ctRRMM-PI score. Log-rank test.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal